Patent Drug - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512245855

Publication Date:

December 6, 2024

Pages:

149

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

A patent medicine is typically protected and advertised by a trademark and trade name (and sometimes a patent) and claimed to be effective against minor disorders and symptoms.
The global market for Patent Drug was estimated to be worth US$ 1071000 million in 2023 and is forecast to a readjusted size of US$ 1507000 million by 2030 with a CAGR of 5.0% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Patent Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Patent Drug by region & country, by Type, and by Application.
The Patent Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Patent Drug.
麻豆原创 Segmentation
By Company
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
AbbVie
Takeda
Boehringer Ingelheim
Takeda
Segment by Type:
Oral
Injection
Other
Segment by Application
Hospital
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Patent Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Patent Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Patent Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Patent Drug Product Introduction
1.2 Global Patent Drug 麻豆原创 Size Forecast
1.3 Patent Drug 麻豆原创 Trends & Drivers
1.3.1 Patent Drug Industry Trends
1.3.2 Patent Drug 麻豆原创 Drivers & Opportunity
1.3.3 Patent Drug 麻豆原创 Challenges
1.3.4 Patent Drug 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Patent Drug Players Revenue Ranking (2023)
2.2 Global Patent Drug Revenue by Company (2019-2024)
2.3 Key Companies Patent Drug Manufacturing Base Distribution and Headquarters
2.4 Key Companies Patent Drug Product Offered
2.5 Key Companies Time to Begin Mass Production of Patent Drug
2.6 Patent Drug 麻豆原创 Competitive Analysis
2.6.1 Patent Drug 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Patent Drug Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Patent Drug as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral
3.1.2 Injection
3.1.3 Other
3.2 Global Patent Drug Sales Value by Type
3.2.1 Global Patent Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Patent Drug Sales Value, by Type (2019-2030)
3.2.3 Global Patent Drug Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Retail Pharmacy
4.2 Global Patent Drug Sales Value by Application
4.2.1 Global Patent Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Patent Drug Sales Value, by Application (2019-2030)
4.2.3 Global Patent Drug Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Patent Drug Sales Value by Region
5.1.1 Global Patent Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Patent Drug Sales Value by Region (2019-2024)
5.1.3 Global Patent Drug Sales Value by Region (2025-2030)
5.1.4 Global Patent Drug Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Patent Drug Sales Value, 2019-2030
5.2.2 North America Patent Drug Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Patent Drug Sales Value, 2019-2030
5.3.2 Europe Patent Drug Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Patent Drug Sales Value, 2019-2030
5.4.2 Asia Pacific Patent Drug Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Patent Drug Sales Value, 2019-2030
5.5.2 South America Patent Drug Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Patent Drug Sales Value, 2019-2030
5.6.2 Middle East & Africa Patent Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Patent Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Patent Drug Sales Value
6.3 United States
6.3.1 United States Patent Drug Sales Value, 2019-2030
6.3.2 United States Patent Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Patent Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Patent Drug Sales Value, 2019-2030
6.4.2 Europe Patent Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Patent Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Patent Drug Sales Value, 2019-2030
6.5.2 China Patent Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Patent Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Patent Drug Sales Value, 2019-2030
6.6.2 Japan Patent Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Patent Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Patent Drug Sales Value, 2019-2030
6.7.2 South Korea Patent Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Patent Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Patent Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Patent Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Patent Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Patent Drug Sales Value, 2019-2030
6.9.2 India Patent Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Patent Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Profile
7.1.2 Pfizer Main Business
7.1.3 Pfizer Patent Drug Products, Services and Solutions
7.1.4 Pfizer Patent Drug Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Recent Developments
7.2 Roche
7.2.1 Roche Profile
7.2.2 Roche Main Business
7.2.3 Roche Patent Drug Products, Services and Solutions
7.2.4 Roche Patent Drug Revenue (US$ Million) & (2019-2024)
7.2.5 Roche Recent Developments
7.3 Sanofi
7.3.1 Sanofi Profile
7.3.2 Sanofi Main Business
7.3.3 Sanofi Patent Drug Products, Services and Solutions
7.3.4 Sanofi Patent Drug Revenue (US$ Million) & (2019-2024)
7.3.5 Johnson & Johnson Recent Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Profile
7.4.2 Johnson & Johnson Main Business
7.4.3 Johnson & Johnson Patent Drug Products, Services and Solutions
7.4.4 Johnson & Johnson Patent Drug Revenue (US$ Million) & (2019-2024)
7.4.5 Johnson & Johnson Recent Developments
7.5 Merck & Co. (MSD)
7.5.1 Merck & Co. (MSD) Profile
7.5.2 Merck & Co. (MSD) Main Business
7.5.3 Merck & Co. (MSD) Patent Drug Products, Services and Solutions
7.5.4 Merck & Co. (MSD) Patent Drug Revenue (US$ Million) & (2019-2024)
7.5.5 Merck & Co. (MSD) Recent Developments
7.6 Novartis
7.6.1 Novartis Profile
7.6.2 Novartis Main Business
7.6.3 Novartis Patent Drug Products, Services and Solutions
7.6.4 Novartis Patent Drug Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis Recent Developments
7.7 AbbVie
7.7.1 AbbVie Profile
7.7.2 AbbVie Main Business
7.7.3 AbbVie Patent Drug Products, Services and Solutions
7.7.4 AbbVie Patent Drug Revenue (US$ Million) & (2019-2024)
7.7.5 AbbVie Recent Developments
7.8 Gilead Sciences
7.8.1 Gilead Sciences Profile
7.8.2 Gilead Sciences Main Business
7.8.3 Gilead Sciences Patent Drug Products, Services and Solutions
7.8.4 Gilead Sciences Patent Drug Revenue (US$ Million) & (2019-2024)
7.8.5 Gilead Sciences Recent Developments
7.9 GlaxoSmithKline (GSK)
7.9.1 GlaxoSmithKline (GSK) Profile
7.9.2 GlaxoSmithKline (GSK) Main Business
7.9.3 GlaxoSmithKline (GSK) Patent Drug Products, Services and Solutions
7.9.4 GlaxoSmithKline (GSK) Patent Drug Revenue (US$ Million) & (2019-2024)
7.9.5 GlaxoSmithKline (GSK) Recent Developments
7.10 Amgen
7.10.1 Amgen Profile
7.10.2 Amgen Main Business
7.10.3 Amgen Patent Drug Products, Services and Solutions
7.10.4 Amgen Patent Drug Revenue (US$ Million) & (2019-2024)
7.10.5 Amgen Recent Developments
7.11 AstraZeneca
7.11.1 AstraZeneca Profile
7.11.2 AstraZeneca Main Business
7.11.3 AstraZeneca Patent Drug Products, Services and Solutions
7.11.4 AstraZeneca Patent Drug Revenue (US$ Million) & (2019-2024)
7.11.5 AstraZeneca Recent Developments
7.12 Bristol-Myers Squibb
7.12.1 Bristol-Myers Squibb Profile
7.12.2 Bristol-Myers Squibb Main Business
7.12.3 Bristol-Myers Squibb Patent Drug Products, Services and Solutions
7.12.4 Bristol-Myers Squibb Patent Drug Revenue (US$ Million) & (2019-2024)
7.12.5 Bristol-Myers Squibb Recent Developments
7.13 Eli Lilly
7.13.1 Eli Lilly Profile
7.13.2 Eli Lilly Main Business
7.13.3 Eli Lilly Patent Drug Products, Services and Solutions
7.13.4 Eli Lilly Patent Drug Revenue (US$ Million) & (2019-2024)
7.13.5 Eli Lilly Recent Developments
7.14 Teva
7.14.1 Teva Profile
7.14.2 Teva Main Business
7.14.3 Teva Patent Drug Products, Services and Solutions
7.14.4 Teva Patent Drug Revenue (US$ Million) & (2019-2024)
7.14.5 Teva Recent Developments
7.15 Bayer
7.15.1 Bayer Profile
7.15.2 Bayer Main Business
7.15.3 Bayer Patent Drug Products, Services and Solutions
7.15.4 Bayer Patent Drug Revenue (US$ Million) & (2019-2024)
7.15.5 Bayer Recent Developments
7.16 Novo Nordisk
7.16.1 Novo Nordisk Profile
7.16.2 Novo Nordisk Main Business
7.16.3 Novo Nordisk Patent Drug Products, Services and Solutions
7.16.4 Novo Nordisk Patent Drug Revenue (US$ Million) & (2019-2024)
7.16.5 Novo Nordisk Recent Developments
7.17 AbbVie
7.17.1 AbbVie Profile
7.17.2 AbbVie Main Business
7.17.3 AbbVie Patent Drug Products, Services and Solutions
7.17.4 AbbVie Patent Drug Revenue (US$ Million) & (2019-2024)
7.17.5 AbbVie Recent Developments
7.18 Takeda
7.18.1 Takeda Profile
7.18.2 Takeda Main Business
7.18.3 Takeda Patent Drug Products, Services and Solutions
7.18.4 Takeda Patent Drug Revenue (US$ Million) & (2019-2024)
7.18.5 Takeda Recent Developments
7.19 Boehringer Ingelheim
7.19.1 Boehringer Ingelheim Profile
7.19.2 Boehringer Ingelheim Main Business
7.19.3 Boehringer Ingelheim Patent Drug Products, Services and Solutions
7.19.4 Boehringer Ingelheim Patent Drug Revenue (US$ Million) & (2019-2024)
7.19.5 Boehringer Ingelheim Recent Developments
7.20 Takeda
7.20.1 Takeda Profile
7.20.2 Takeda Main Business
7.20.3 Takeda Patent Drug Products, Services and Solutions
7.20.4 Takeda Patent Drug Revenue (US$ Million) & (2019-2024)
7.20.5 Takeda Recent Developments
8 Industry Chain Analysis
8.1 Patent Drug Industrial Chain
8.2 Patent Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Patent Drug Sales Model
8.5.2 Sales Channel
8.5.3 Patent Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
AbbVie
Takeda
Boehringer Ingelheim
Takeda

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.